Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Tavapadon will enter a competitive but commercially attractive market after a likely regulatory submission following post-hoc data.

Results provide evidence needed to challenge the step-through reimbursement requirements that have restricted Qulipta's uptake in Europe.

The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.

In April 2026, Biogen announced that it would acquire exclusive rights to TJ Biopharma’s felzartamab in Greater China for up to $850m.